NCT07144098View on ClinicalTrials.gov

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

July 12, 2026

Study Completion Date

January 26, 2027

Conditions
Obesity/Overweight
Interventions
DRUG

GZR18 injection

3 mg-Control group

DRUG

GZR18 injection

3 mg-mild liver insufficiency

DRUG

GZR18 injection

3 mg-moderate liver insufficiency

DRUG

GZR18 injection

3 mg-severe liver insufficiency

Trial Locations (1)

Unknown

RECRUITING

Gan & Lee Pharmaceuticals, Beijing

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY